Cargando…

The pan-cancer pathological regulatory landscape

Dysregulation of the normal gene expression program is the cause of a broad range of diseases, including cancer. Detecting the specific perturbed regulators that have an effect on the generation and the development of the disease is crucial for understanding the disease mechanism and for taking deci...

Descripción completa

Detalles Bibliográficos
Autores principales: Falco, Matias M., Bleda, Marta, Carbonell-Caballero, José, Dopazo, Joaquín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175166/
https://www.ncbi.nlm.nih.gov/pubmed/28000771
http://dx.doi.org/10.1038/srep39709
_version_ 1782484608210698240
author Falco, Matias M.
Bleda, Marta
Carbonell-Caballero, José
Dopazo, Joaquín
author_facet Falco, Matias M.
Bleda, Marta
Carbonell-Caballero, José
Dopazo, Joaquín
author_sort Falco, Matias M.
collection PubMed
description Dysregulation of the normal gene expression program is the cause of a broad range of diseases, including cancer. Detecting the specific perturbed regulators that have an effect on the generation and the development of the disease is crucial for understanding the disease mechanism and for taking decisions on efficient preventive and curative therapies. Moreover, detecting such perturbations at the patient level is even more important from the perspective of personalized medicine. We applied the Transcription Factor Target Enrichment Analysis, a method that detects the activity of transcription factors based on the quantification of the collective transcriptional activation of their targets, to a large collection of 5607 cancer samples covering eleven cancer types. We produced for the first time a comprehensive catalogue of altered transcription factor activities in cancer, a considerable number of them significantly associated to patient’s survival. Moreover, we described several interesting TFs whose activity do not change substantially in the cancer with respect to the normal tissue but ultimately play an important role in patient prognostic determination, which suggest they might be promising therapeutic targets. An additional advantage of this method is that it allows obtaining personalized TF activity estimations for individual patients.
format Online
Article
Text
id pubmed-5175166
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51751662016-12-28 The pan-cancer pathological regulatory landscape Falco, Matias M. Bleda, Marta Carbonell-Caballero, José Dopazo, Joaquín Sci Rep Article Dysregulation of the normal gene expression program is the cause of a broad range of diseases, including cancer. Detecting the specific perturbed regulators that have an effect on the generation and the development of the disease is crucial for understanding the disease mechanism and for taking decisions on efficient preventive and curative therapies. Moreover, detecting such perturbations at the patient level is even more important from the perspective of personalized medicine. We applied the Transcription Factor Target Enrichment Analysis, a method that detects the activity of transcription factors based on the quantification of the collective transcriptional activation of their targets, to a large collection of 5607 cancer samples covering eleven cancer types. We produced for the first time a comprehensive catalogue of altered transcription factor activities in cancer, a considerable number of them significantly associated to patient’s survival. Moreover, we described several interesting TFs whose activity do not change substantially in the cancer with respect to the normal tissue but ultimately play an important role in patient prognostic determination, which suggest they might be promising therapeutic targets. An additional advantage of this method is that it allows obtaining personalized TF activity estimations for individual patients. Nature Publishing Group 2016-12-21 /pmc/articles/PMC5175166/ /pubmed/28000771 http://dx.doi.org/10.1038/srep39709 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Falco, Matias M.
Bleda, Marta
Carbonell-Caballero, José
Dopazo, Joaquín
The pan-cancer pathological regulatory landscape
title The pan-cancer pathological regulatory landscape
title_full The pan-cancer pathological regulatory landscape
title_fullStr The pan-cancer pathological regulatory landscape
title_full_unstemmed The pan-cancer pathological regulatory landscape
title_short The pan-cancer pathological regulatory landscape
title_sort pan-cancer pathological regulatory landscape
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175166/
https://www.ncbi.nlm.nih.gov/pubmed/28000771
http://dx.doi.org/10.1038/srep39709
work_keys_str_mv AT falcomatiasm thepancancerpathologicalregulatorylandscape
AT bledamarta thepancancerpathologicalregulatorylandscape
AT carbonellcaballerojose thepancancerpathologicalregulatorylandscape
AT dopazojoaquin thepancancerpathologicalregulatorylandscape
AT falcomatiasm pancancerpathologicalregulatorylandscape
AT bledamarta pancancerpathologicalregulatorylandscape
AT carbonellcaballerojose pancancerpathologicalregulatorylandscape
AT dopazojoaquin pancancerpathologicalregulatorylandscape